ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
1-Year Return
169.78%
This Quarter Return
+23.97%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$71.6M
AUM Growth
-$14.6M
(-17%)
Cap. Flow
-$22.5M
Cap. Flow
% of AUM
-31.35%
Top 10 Holdings %
Top 10 Hldgs %
72.06%
Holding
37
New
3
Increased
6
Reduced
14
Closed
9
Top Buys
| 1 |
Cidara Therapeutics
CDTX
|
+$2.62M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
+$1.77M |
| 3 |
Taysha Gene Therapies
TSHA
|
+$1.12M |
| 4 |
Akero Therapeutics
AKRO
|
+$1.06M |
| 5 |
Terns Pharmaceuticals
TERN
|
+$516K |
Top Sells
| 1 |
Insmed
INSM
|
+$6.94M |
| 2 |
Enliven Therapeutics
ELVN
|
+$5.22M |
| 3 |
Tourmaline Bio
TRML
|
+$2.29M |
| 4 |
Merck
MRK
|
+$2.06M |
| 5 |
Ocular Therapeutix
OCUL
|
+$1.9M |
Sector Composition
| 1 | Healthcare | 99.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RAPP
26
Rapport Therapeutics
RAPP
$1.1B
| $227K | 0.32% |
20,000
+3,600
| +22% | +$40.9K |
|
|
ARTV
27
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$62.3M
| $68.6K | 0.1% |
45,456
| – | – |
|
28
Nuvation Bio Inc. Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50
NUVB.WS
$64.6M
| $24.5K | 0.03% |
90,832
| – | – |
|
|
29
Enliven Therapeutics
ELVN
$1.18B
| – | – |
-265,269
| Closed | -$5.22M |
|
30
Edgewise Therapeutics
EWTX
$1.5B
| – | – |
-85,454
| Closed | -$1.88M |
|
31
Forte Biosciences
FBRX
$131M
| – | – |
-18,469
| Closed | -$143K |
|
32
Gilead Sciences
GILD
$142B
| – | – |
-9,298
| Closed | -$1.04M |
|
|
MREO
33
Mereo BioPharma
MREO
$294M
| – | – |
-791,815
| Closed | -$1.78M |
|
|
34
Merck
MRK
$207B
| – | – |
-22,994
| Closed | -$2.06M |
|
35
Rocket Pharmaceuticals
RCKT
$341M
| – | – |
-83,350
| Closed | -$556K |
|
|
VERV
36
DELISTED
Verve Therapeutics
VERV
| – | – |
-162,724
| Closed | -$744K |
|